About Omixon

About Omixon

Omixon is a global transplantation diagnostic company with a mission to provide histocompatibility laboratories with innovative technologies to improve transplant outcomes. Omixon is headquartered in Budapest, Hungary, with operations in the United States, Brazil and the Netherlands serving more than 60 laboratories worldwide.

Building on multidisciplinary competences in bioinformatics, software engineering, molecular biology and regulatory science, Omixon transforms molecular biology innovations into state-of-the-art products in transplant diagnostics.

Omixon was the first to successfully introduce NGS-based HLA typing kit and software in 2014 by bringing Holotype HLA, an NGS-based HLA genotyping product, and HLA Twin software to market. Omixon Twin delivers the most accurate high-resolution HLA genotyping and is used in more than 60+ laboratories worldwide.

Omixon was the first to release a high-resolution HLA genotyping product NanoTYPE HLA™ with less than 5 hours turnaround time on the Oxford Nanopore sequencing platform complemented by NanoTYPER™ analysis software.

Omixon is the first to bring to market the first donor-derived cell-free DNA kit HoloGRAFT for laboratories with donor-informative genetic markers with primer and probe sequences that are absent in the patient genotype by design.


Company Milestones

In 2009 we just had a roadmap, ideas and plans to develop a global molecular diagnostics company in the field of Next Generation Sequencing. We managed to find out our direction and have become a significant player on the HLA-typing market.

2011Omixon founded.

2012Seed Funding Milestone, Omixon launches Target software.

2014 MayOmixon announces exclusive license with the Children’s Hospital of Philadelphia for Holotype HLA, Raises Capital, Launches US Office.

2014 SeptOmixon launches Holotype HLA via Early Access, first NGS-based HLA typing product.

2015 FebOmixon expands offices in Budapest.
2016 JanOmixon announces Major Tender Victory in France.
2016 MarchOmixon announces  CE Mark for Holotype HLA.
2017 Omixon launches HLA Explore for HLA Researchers.
2018Omixon launches Monotype ABO molecular typing kit.
2019 Omixon Launches OmniType via Early Access, 11 loci multiplex product for HLA typing by NGS
2020 Omixon announces Omixon launches AzureSeq-200 CE IVD kit For one-step RT-qPCR detection of SARS-CoV-2 via an exclusive agreement with SeqOnce Biosciences
2021 Omixon developed NanoTYPE™, a nanopore-based long-read sequencing technology offering high resolution HLA typing under six hours. At the same time, Omixon entered the post-transplant market with HoloGRAFT™, a laboratory kit monitoring absolute quantity of donor derived cfDNA

Our Expertise

Our Executive Team have spent more than a decade leading Software, NGS and genomics companies. Our Research and Development Team have a mixture of experience in all aspects of molecular diagnostics, with experts in software development, bioinformatics and genomics. Professor Dimitri Monos who serves as Chairman of the Scientific Advisory Board was one of the pioneers of NGS for HLA, and the inventor of the Holotype. Our major collaborators and key opinion leaders in the HLA community have provided the highest level of leadership within the community for several decades and Omixon has evolved into a global molecular diagnostics company that currently focuses on driving the adoption of NGS in the clinic with Holotype HLA, an NGS-based HLA genotyping Assay and Software product.